GleamWall
中文EN

RTGN RetinalGenix Technologies Inc.

Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1836295 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY26.9%
TTM EPS YoY33.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-34,441.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets46,768.1%
Debt / equity—
Current ratio0.00x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.23x
Accruals ratio-26,393.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$83,040$373,271
SG&A expense$1.30M$1.33M
Interest expense$4,005$3,840
Net income-$2.43M-$4.32M
EPS (basic)-0.13-0.24
EPS (diluted)-0.13-0.24
Weighted avg. shares (diluted)18.56M17.94M
Balance sheet
Cash & equivalents$14,774$6,060
Current assets$14,774$6,060
PP&E, net—$56
Total assets$21,041$14,946
Current liabilities$2.32M$1.47M
Total liabilities$2.32M$1.48M
Shareholders' equity-$2.30M-$1.46M
Shares outstanding18.75M18.52M
Cash flow statement
Operating cash flow-$558,350-$741,936
Financing cash flow$567,064$747,996
Depreciation & amortization$56$100
Stock-based compensation$1.04M$2.61M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.